1. 1. Almakaeva LG, Begunova NV, Naumenok LG, Dolya VG, Almakaev МS. Development of composition of infusion medication on basis of moxifloxacin. Annals of Mechnikov Institute. 2015;2:70-3 (in Ukrainian).
2. 2. Dudikova ML, Vrynchanu NO, Dronova ML. New antibiotics of the quinolone series: prospects for use in medical practice. Pharmacology and Medical Toxicology. 2015;1(432), 3-12 (in Ukrainian).
3. 3. Ferrandiz MJ, Martin-Galiano AJ, Arnanz C, Zimmerman T, de la Campa AG. Reactive oxygen species contribute to the bactericidal effects of the fluoroquinolone moxifloxacin in Streptococcus pneumonia. Antimicrobial Agents and Chemotherapy. 2016;60(1):409-17. doi: 10.1128/aac.02299-15.
4. 4. Paliy GK, Nazarchuk OA, Nahajchuk VI, Osadchuk NI, Paliy DV, Kovalenko IV. Analytic prognostication of sensitivity of staphilococcus to fluoroquinolones. Svit Medicini i Biologii. 2015;3(51):103-6 (in Ukrainian).
5. 5. Ambulkar PS, Ghosh SK, Indole IV, Pal AK. Genotoxic and cytotoxic effects of antibacterial drug, ciprofloxacin, on human lymphocytes in vitro. Nepal Medical College Journal. 2009;11(3):147-51.